

Technology Advisory Committee A Interests Register

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy [ID6191]

Publication Date: 27 March 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
James Fotheringham	TAC A Committee Member	Direct - Financial	James has received research funding to perform a targeted literature review on resistant and uncontrolled hypertension, paid to my institution.	07/12/2023	It was agreed that James' declaration would not prevent him from participating in discussions on this appraisal.
Professor Ian McNeish	Clinical Expert	Direct – financial	Ian has sat on Advisory Boards for AstraZeneca – these have all related to the use of PARP inhibitor therapy in ovarian cancer	25/07/2023	It was agreed that Ian's declaration would not prevent him from participating in discussions on this appraisal.